Compare Stocks: KARD, MIRM, PTCT, and COGT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$29.51 +4.8%	$34.20	$13.78 ▼ $43.73	$5.12B	0.31	2.18 million shs	3.04 million shs
KARD Kardigan	$13.88 +2.7%	$18.05	$12.23 ▼ $27.00	$1.30B	N/A	517,309 shs	660,930 shs
MIRM Mirum Pharmaceuticals	$82.39 +3.0%	$93.46	$63.23 ▼ $130.00	$5.35B	0.61	855,387 shs	605,233 shs
PTCT PTC Therapeutics	$60.99 +2.2%	$67.89	$58.80 ▼ $90.87	$5.09B	0.49	1.37 million shs	1.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	+0.21%	-6.60%	-15.74%	-25.80%	+82.44%
KARD Kardigan	+4.24%	-2.24%	-29.03%	-35.68%	+1,351,999,900.00%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%
PTCT PTC Therapeutics	-0.42%	-5.63%	-10.24%	-24.01%	-9.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$29.51 +4.8%	$34.20	$13.78 ▼ $43.73	$5.12B	0.31	2.18 million shs	3.04 million shs
KARD Kardigan	$13.88 +2.7%	$18.05	$12.23 ▼ $27.00	$1.30B	N/A	517,309 shs	660,930 shs
MIRM Mirum Pharmaceuticals	$82.39 +3.0%	$93.46	$63.23 ▼ $130.00	$5.35B	0.61	855,387 shs	605,233 shs
PTCT PTC Therapeutics	$60.99 +2.2%	$67.89	$58.80 ▼ $90.87	$5.09B	0.49	1.37 million shs	1.05 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	+0.21%	-6.60%	-15.74%	-25.80%	+82.44%
KARD Kardigan	+4.24%	-2.24%	-29.03%	-35.68%	+1,351,999,900.00%
MIRM Mirum Pharmaceuticals	+0.43%	-0.84%	-17.35%	-31.87%	+9.12%
PTCT PTC Therapeutics	-0.42%	-5.63%	-10.24%	-24.01%	-9.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	74.71% Upside
KARD Kardigan	2.71	Moderate Buy	$38.80	179.54% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$147.88	79.48% Upside
PTCT PTC Therapeutics	2.69	Moderate Buy	$97.62	60.05% Upside

Current Analyst Ratings Breakdown

Latest KARD, MIRM, PTCT, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	PTCT PTC Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$80.00 ➝ $90.00
10/14/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$136.00 ➝ $156.00
10/13/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$146.00
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$137.00 ➝ $152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	KARD Kardigan	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$25.00
10/12/2026	KARD Kardigan	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$195.00 ➝ $200.00
10/8/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$135.00 ➝ $155.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	$618.07M	8.66	$0.05 per share	1,561.82	$6.12 per share	13.46
PTCT PTC Therapeutics	$1.73B	2.94	$8.93 per share	6.83	($2.56) per share	-23.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
KARD Kardigan	-$191.94M	-$2.88	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	29.75	1.81	-3.80%	N/A	-1.32%	11/3/2026 (Estimated)

Latest KARD, MIRM, PTCT, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	COGT Cogent Biosciences	-$0.5554	N/A	N/A	N/A	$0.75 million	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.4889	N/A	N/A	N/A	$178.06 million	N/A
11/3/2026	Q3 2026	PTCT PTC Therapeutics	$0.2969	N/A	N/A	N/A	$302.83 million	N/A
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	0.48	13.57	13.57
KARD Kardigan	N/A	8.72	8.72
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
KARD Kardigan	N/A
MIRM Mirum Pharmaceuticals	N/A
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	6.59%
KARD Kardigan	N/A
MIRM Mirum Pharmaceuticals	8.32%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	258	173.53 million	162.09 million	Optionable
KARD Kardigan	241	93.50 million	N/A	N/A
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

KARD, MIRM, PTCT, and COGT Headlines

Recent News About These Companies

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

October 15 at 8:00 AM | prnewswire.com

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock

October 13 at 7:07 PM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month Low - Time to Sell?

October 13 at 12:39 PM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $158,475.00 in Stock

October 12 at 4:09 AM | americanbankingnews.com

PTC Therapeutics (PTCT) Gets a Hold from RBC Capital

October 10, 2026 | theglobeandmail.com

PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Michael Schmertzler Sells 2,500 Shares

October 10, 2026 | insidertrades.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 10, 2026 | americanbankingnews.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages

October 10, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock Gets Downgrade from Wall Street Zen

October 10, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock

October 9, 2026 | marketbeat.com

RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating

October 8, 2026 | marketscreener.comM

PTC Therapeutics (NASDAQ:PTCT) VP Sells 435 Shares of Company Stock

October 8, 2026 | insidertrades.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock

October 7, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares

October 7, 2026 | marketbeat.com

PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says

October 7, 2026 | marketscreener.comM

Cantor raises target for PTC Therapeutics stock to USD 137.00

October 7, 2026 | ad-hoc-news.deA

PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,000 Shares of Stock

October 3, 2026 | insidertrades.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock

October 2, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7% - Here's What Happened

September 28, 2026 | marketbeat.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 25, 2026 | prnewswire.com

PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 22, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KARD, MIRM, PTCT, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

$29.51 +1.36 (+4.83%)

Closing price 04:00 PM Eastern

Extended Trading

$29.52 +0.01 (+0.05%)

As of 07:30 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Kardigan NASDAQ:KARD

$13.88 +0.36 (+2.66%)

As of 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$82.39 +2.43 (+3.04%)

Closing price 04:00 PM Eastern

Extended Trading

$82.42 +0.03 (+0.04%)

As of 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

PTC Therapeutics NASDAQ:PTCT

$60.99 +1.32 (+2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$60.97 -0.02 (-0.03%)

As of 07:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KARD, MIRM, PTCT, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KARD, MIRM, PTCT, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KARD, MIRM, PTCT, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KARD, MIRM, PTCT, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Kardigan NASDAQ:KARD

Mirum Pharmaceuticals NASDAQ:MIRM

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KARD, MIRM, PTCT, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KARD, MIRM, PTCT, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KARD, MIRM, PTCT, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KARD, MIRM, PTCT, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Kardigan NASDAQ:KARD

Mirum Pharmaceuticals NASDAQ:MIRM

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools